Vorinostat
Vorinostat (Zolinza) was the first drug of its kind, a capsule that loosens the chemical packaging of DNA. It treats the skin disease of cutaneous T-cell lymphoma after two other treatments have failed.
Overview
Vorinostat was approved by the FDA in October 2006 for cutaneous manifestations of cutaneous T-cell lymphoma in patients with progressive, persistent or recurrent disease on or after two systemic therapies, on two open-label studies (response rate about 30% in the pivotal single-arm study of 74 patients). It was the first histone deacetylase inhibitor approved for any cancer and remains a standard option in refractory mycosis fungoides and Sezary syndrome; a European application was withdrawn and it is not authorised in the EU. Fatigue, diarrhoea, thrombocytopenia, taste change and QT prolongation are the main adverse effects; thromboembolism is a class warning.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas: how tumours escape and what closes the route · Lines of therapy.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2006 | Cutaneous manifestations of CTCL with progressive, persistent or recurrent disease after two systemic therapies |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Notes
top- Cutaneous T-cell lymphoma has no cancer record yet.
Latest papers
topQuery for this drug: (TITLE:"Vorinostat" OR ABSTRACT:"Vorinostat" OR TITLE:"Zolinza" OR ABSTRACT:"Zolinza" OR TITLE:"SAHA" OR ABSTRACT:"SAHA" OR TITLE:"Suberoylanilide hydroxamic acid" OR ABSTRACT:"Suberoylanilide hydroxamic acid") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Vorinostat, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductDecitabine
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET) and the tag nci-list.
- ProductSelumetinib
Shares Merck & Co. (MSD) and the tag nci-list.
- ProductBelinostat
Shares Histone deacetylases (HDAC), Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
- ProductHPV quadrivalent vaccine (types 6, 11, 16 and 18)
Shares Merck & Co. (MSD) and the tag nci-list.
- ProductAprepitant (and fosaprepitant)
Shares Merck & Co. (MSD) and the tag nci-list.
- CancerPeripheral T-cell lymphomas (including cutaneous T-cell lymphoma)
Shares Romidepsin, Histone deacetylases (HDAC), Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).